SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-140619
Filing Date
2021-04-29
Accepted
2021-04-29 16:40:02
Documents
13
Period of Report
2021-04-29
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d180476d8k.htm   iXBRL 8-K 26910
2 EX-99.1 d180476dex991.htm EX-99.1 13039
  Complete submission text file 0001193125-21-140619.txt   171991

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA labp-20210429.xsd EX-101.SCH 3093
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE labp-20210429_lab.xml EX-101.LAB 18887
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE labp-20210429_pre.xml EX-101.PRE 11875
6 EXTRACTED XBRL INSTANCE DOCUMENT d180476d8k_htm.xml XML 3471
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

IRS No.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39971 | Film No.: 21871397
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences